Advertisement

Topics

PARP Inhibition Appears Promising in CRPC, But Questions Remain

11:09 EDT 17 May 2019 | OncLive

PARP inhibitors alone and in combinations are demonstrating potential in castration-resistant prostate cancer, but questions about survival benefit, toxicities, and efficacy remain to be answered.

Original Article: PARP Inhibition Appears Promising in CRPC, But Questions Remain

NEXT ARTICLE

More From BioPortfolio on "PARP Inhibition Appears Promising in CRPC, But Questions Remain"

Advertisement
Quick Search
Advertisement
Advertisement